2013
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia
Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, Kim YM. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013, 33: 2169-2178. PMID: 23728349, PMCID: PMC3994178, DOI: 10.1038/onc.2013.169.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAsparaginaseBeta CateninBridged Bicyclo Compounds, HeterocyclicCell Line, TumorCell ProliferationCell SurvivalDexamethasoneDown-RegulationDrug Resistance, NeoplasmDrug SynergismHumansInhibitor of Apoptosis ProteinsMiceMice, Inbred NODMice, SCIDMutationPeptide FragmentsPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrimidinonesSialoglycoproteinsSurvivinVincristineWnt Signaling PathwayXenograft Model Antitumor AssaysConceptsICG-001Activation of genesDivergent cellular responsesProgenitor cellsInitiation of differentiationSmall molecule modulatorsAcute lymphoblastic leukemiaAmino acids 1Small molecule inhibitionWnt/cateninNovel small molecule modulatorsPrimary acute lymphoblastic leukemiaCoactivator CBPChromatin immunoprecipitationTranscriptional activationHematopoietic progenitor cellsSelf-renewal capacityApoptosis proteinNormal hematopoietic progenitor cellsCBP mutationsN-terminusCellular responsesCatenin interactionC-terminalSurvivin promoter
2011
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011, 118: 2191-2199. PMID: 21715311, PMCID: PMC3162353, DOI: 10.1182/blood-2011-04-351239.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCombined Modality TherapyDrug Resistance, NeoplasmGene ExpressionGene TargetingHumansInhibitor of Apoptosis ProteinsMiceMice, Inbred NODMice, KnockoutNeoplasm, ResidualOligonucleotidesPrecursor Cell Lymphoblastic Leukemia-LymphomaRepressor ProteinsRNA, Small InterferingSurvivinTumor Stem Cell AssayXenograft Model Antitumor AssaysConceptsAcute lymphoblastic leukemiaDrug resistanceLymphoblastic leukemiaDrug-resistant acute lymphoblastic leukemiaDetectable minimal residual diseasePrimary acute lymphoblastic leukemiaNucleic acid antisense oligonucleotideMinimal residual diseaseInhibition of survivinResidual diseaseSurvival advantageXenograft modelSurvivin expressionSurvivin inhibitionLeukemiaSurvivinChemotherapyRelapseAntisense oligonucleotideSurvivin/BIRC5Present studyApoptosis proteinInhibitionCellsPatients